Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling
Xiwu Chen, Hongtao Wang, Hong-Jun Liao, Wen Hu, Leslie Gewin, Glenda Mernaugh, Sheng Zhang, Zhong-Yin Zhang, Lorenzo Vega-Montoto, Roberto M. Vanacore, Reinhard Fässler, Roy Zent, Ambra Pozzi
Xiwu Chen, Hongtao Wang, Hong-Jun Liao, Wen Hu, Leslie Gewin, Glenda Mernaugh, Sheng Zhang, Zhong-Yin Zhang, Lorenzo Vega-Montoto, Roberto M. Vanacore, Reinhard Fässler, Roy Zent, Ambra Pozzi
View: Text | PDF
Research Article Nephrology

Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling

  • Text
  • PDF
Abstract

Tubulointerstitial fibrosis underlies all forms of end-stage kidney disease. TGF-β mediates both the development and the progression of kidney fibrosis through binding and activation of the serine/threonine kinase type II TGF-β receptor (TβRII), which in turn promotes a TβRI-mediated SMAD-dependent fibrotic signaling cascade. Autophosphorylation of serine residues within TβRII is considered the principal regulatory mechanism of TβRII-induced signaling; however, there are 5 tyrosine residues within the cytoplasmic tail that could potentially mediate TβRII-dependent SMAD activation. Here, we determined that phosphorylation of tyrosines within the TβRII tail was essential for SMAD-dependent fibrotic signaling within cells of the kidney collecting duct. Conversely, the T cell protein tyrosine phosphatase (TCPTP) dephosphorylated TβRII tail tyrosine residues, resulting in inhibition of TβR-dependent fibrotic signaling. The collagen-binding receptor integrin α1β1 was required for recruitment of TCPTP to the TβRII tail, as mice lacking this integrin exhibited impaired TCPTP-mediated tyrosine dephosphorylation of TβRII that led to severe fibrosis in a unilateral ureteral obstruction model of renal fibrosis. Together, these findings uncover a crosstalk between integrin α1β1 and TβRII that is essential for TβRII-mediated SMAD activation and fibrotic signaling pathways.

Authors

Xiwu Chen, Hongtao Wang, Hong-Jun Liao, Wen Hu, Leslie Gewin, Glenda Mernaugh, Sheng Zhang, Zhong-Yin Zhang, Lorenzo Vega-Montoto, Roberto M. Vanacore, Reinhard Fässler, Roy Zent, Ambra Pozzi

×

Figure 9

Y336 and Y470 in the cytoplasmic tail of TβRII regulate EMT.

Options: View larger image (or click on image) Download as PowerPoint
Y336 and Y470 in the cytoplasmic tail of TβRII regulate EMT.
(A) α1KO Tβ...
(A) α1KO TβRIIfl/fl CD cells were left untreated (–Cre) or treated with adeno-Cre (Cre) to downregulate TβRII. Cells were then transfected with empty vector (Cre/Vo), WT TβRII (Cre/TβRII), or TβRII constructs mutated in 1 or more of the 3 tyrosines (as indicated), and their morphology was evaluated. (B) HEK293 cells were transiently transfected with empty pEGFP-N2 vector (EGFP), WT TβRII (TβRII/EGFP), or TβRII constructs mutated in 1 (TβRIIY284A/EGFP and TβRIIY470A/EGFP) or multiple (TβRIIY336/470A/EGFP and TβRIIY284/336/470A/EGFP) tyrosines. After 72 hours, the membrane localization (asterisks) of the various TβRII constructs was evaluated by analyzing the cells under an epifluorescence microscope. (C and D) Cell lysates (20 μg/lane) from the serum-starved CD cell populations indicated were analyzed by Western blot for levels of TβRII, pSMAD3, SMAD3, collagen IV, and E-cadherin. Lanes were run on the same gel but were noncontiguous (black lines). (E) The indicated CD cell populations were serum starved for 24 hours, then treated or not with TGF-β1 for 30 minutes. Cell lysates (20 μg/lane) were analyzed by Western blot for levels of TβRII, pSMAD3, and SMAD3. (F and G) Cell lysates (0.5 mg) from the serum-starved CD cell populations indicated were immunoprecipitated with anti-human TβRII antibodies (2 μg) (F) or with 4G10 (10 μg) or mouse IgG isotype control antibody (10 μg) (G), then analyzed by Western blot. A band corresponding to TβRII was more tyrosine phosphorylated (F) and more evident (G) in lysates of CD cells expressing WT than Y284/336/470A TβRII. Scale bars: 20 μm (A); 5 μm (B).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts